Quantcast

Industry news that matters to you.  Learn more

Contract Research Organizations To Adopt Ion Torrent Next-Generation Sequencing Platform

Two Contract Research Organizations (CROs) with leading expertise in molecular testing have decided to utilize the new Oncomine Cancer Research panel, which runs on Life Technologies Ion Torrent sequencing instruments, for clinical trial analyses and design.

Next-Generation Flow Cytometry Instrument Broadens Analysis in Life Science Research

Life science researchers who want to broaden their cell analysis capabilities can now employ a next-generation flow cytometer with a modular design that allows them greater flexibility in applications ranging from biomarker discovery to cancer research.

Life Technologies and Advanced Cell Diagnostics Sign Global Distribution Agreement

Life Technologies Corporation (NASDAQ: LIFE) and Advanced Cell Diagnostics, Inc. (ACD), a leader in the field of molecular pathology and developer of cell and tissue-based analysis tools, recently announced a global distribution agreement by which Life will distribute ACD’s fluorescent RNAscope® portfolio of probes and kits to the research market through its worldwide distribution network.

Multiplicom Launches Three New Mutation Detection Kits to Enable the Implementation of Personalized Cancer Treatment

Multiplicom NV, a specialist in the development, production and commercialization of innovative molecular genetic tests based on massively parallel sequencing (MPS), recently announced that it is launching three new somatic mutation detection kits which will enable users to implement personalized cancer treatment at an unprecedented level.

Life Technologies and RainTree Oncology Services Announce Collaboration to Bring Molecular Tumor Testing to Community Oncologists

Life Technologies Corporation (NASDAQ: LIFE) and RainTree Oncology Services recently announced they have entered into a collaboration agreement designed to further the advancement of personalized care for cancer patients.

Through the collaboration, RainTree and Life Technologies will seek to make the latest advances in molecular testing available to the broader patient market and will work to develop a streamlined protocol for entering patients into clinical trials for new targeted therapies.

Key elements of the collaboration are:

  • Collaborate on matching oncology patients to clinical trials using a Next Generation Sequencing Oncology screening panel;
  • Develop a clinical trials recruitment database which incorporates RainTree’s broad patient data set, enhanced by other data sources, including Life’s Compendia analytics engine;
  • Educate private payors and health plans about the benefits of Next Generation Sequencing; and
  • Build and market comprehensive product, test and data offerings for clinical research organizations.

“Today’s announcement emphasizes RainTree Oncology Services’ commitment to providing access to cutting edge capabilities to the over 600 community oncologists and approximately 40 practices that we serve,” said Mike Martin, chief executive officer of RainTree. “The world of personalized medicine is moving very fast, and the collaboration with Life Technologies ensures we stay active in the development of advanced molecular diagnostic capabilities to connect our physicians and patients with the latest in therapeutic discovery.”

“Our goal is to ensure that patients in the community setting have the same access to advanced technologies, such as genetic sequencing, as patients in the top academic centers,” said Ronnie Andrews, president of genetic and medical sciences at Life Technologies. “This collaboration also establishes a mechanism for pharmaceutical companies to identify the patients they need for clinical trials to bring new, targeted therapies to market.”

“Life Technologies and RainTree Oncology share a mutual commitment to improving cancer care in the community setting, where the majority of patients are diagnosed and treated,” said Andrews.

Through the collaboration, Life Technologies intends to participate in development of next generation sequencing panels that will allow for deep interrogation of tumors. Additional assays may also be developed under the collaboration. Patient data will be housed in a de-identified format in a proprietary database, which will be made available to pharmaceutical companies to recruit Phase 1 patients, as well as to participating clinical research organizations to support recruitment for later phase trials.

The agreement provides for RainTree and Life Technologies to leverage RainTree’s data sets, and utilize the information to enrich patient populations for early phase clinical trials and apply advanced bioinformatics techniques via Life Technologies’ proprietary Compendia Oncomine® solution to help identify targeted therapeutics for trials on certain tumor genotypes.

More than one half of cancer patients are seen in community oncology practices, according to Inside Oncology, Academic Cancer Centers (NCCC). The more than 500 new targeted compounds currently in development are leading to a large unmet need for recruitment of patients based on specific molecular profiles.

“Efficiently identifying clinical trial candidates for new targeted therapies has presented an obstacle in bringing new drugs to market,” said Dr. Jeff Patton, chief medical officer of RainTree and chief executive officer of Tennessee Oncology. “Through our collaboration with Life Technologies, we will be able to tap into new genetic information that, along with our existing data sets, will help guide patients to enroll in clinical trials based on the genetic signatures of their tumors.”

Source: Life Technologies